
    
      This is a randomized, multicenter, open-label phase 2 study of the SINE compound, selinexor
      given orally versus restricted investigator choice (i.e., one of three potential salvage
      therapies).

      Participants who have never been transplant eligible, are currently deemed unfit for
      intensive chemotherapy, â‰¥ 60 years old, who have AML (except Acute Promyelocytic Leukemia:
      APL, AML M3) after one prior treatment of either hypomethylating agent or a regimen including
      Ara-C, and are meeting the inclusion and exclusion criteria will be randomized to receive
      either oral selinexor or physician's choice (one of three potential treatments: best
      supportive care (BSC) alone, or BSC + hypomethylating agent, or BSC + low dose Ara-C until
      disease progression, death or intolerance has occurred.
    
  